By: PR.com
November 13, 2012 at 01:00 AM EST
Sengenics Announces Exclusive Agreement with the Sequenom Center for Molecular Medicine to Provide Its Non-Invasive Prenatal Trisomy Test in Malaysia and Singapore

Kuala Lumpur, Malaysia, November 13, 2012 --(PR.com)-- Sengenics, Asia’s 1st Genetic Diagnostics Company, today announced that it has entered into an exclusive agreement with The Sequenom Center for Molecular Medicine (Sequenom CMM), to launch and promote its MaterniT21 PLUS non-invasive prenatal testing service in Malaysia and Singapore.

Sengenics will work with medical practitioners in the region to prescribe MaterniT21 PLUS for the detection of Trisomy 13, 18 and 21 in expectant mothers. Sengenics has a strong regional footprint and has established channels into the medical sector, with 8 out of ten of the top private hospital chains in the region currently under contract.

“We are delighted to be working with Sequenom CMM, particularly given their success with MaterniT21 PLUS in North America and around the world, a very important consideration for us,” said Dr. Arif Anwar, Executive Director, Sengenics. The test has been widely peer-reviewed, validated and published as the most accurate test for diagnosing the existence of trisomy 21, an indication of Down’s syndrome.

MaterniT21 PLUS is now available through Sengenics’ select panel of partner O&G Clinicians and Hospitals in Malaysia and Singapore.

About Sengenics
Founded in 2008, Sengenics was the 1st company in Asia to offer genomics based diagnostics services. Since its inception, Sengenics has focused upon building key research collaborations and diagnostics facilities throughout Asia. The company has an exclusive strategic partnership with Oxford University Professor Sir Edwin Southern’s company, Oxford Gene Technology (OGT) for Asia.

In addition to providing research and diagnostics services, Sengenics continues to develop its own IP and downstream genomics, proteomics and antibody biomarker based tests.

About Sequenom CMM, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists and maternal fetal medicine specialists, and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Sengenics Enquiries to Mohd Badzlan
www.sengenics.com
enquiries@sengenics.com

Contact Information:
Sengenics
Mohd Badzlan
+60 (0)3 7877 6881
Contact via Email
www.sengenics.com

Click here to read the full story: Sengenics Announces Exclusive Agreement with the Sequenom Center for Molecular Medicine to Provide Its Non-Invasive Prenatal Trisomy Test in Malaysia and Singapore

Press Release Distributed by PR.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here